Convatec, a FTSE 100 medical equipment company, has secured £20 million in government funding to support the development of a new research and development hub in Manchester. The announcement was highlighted in Chancellor John Healey's recent budget speech, which also detailed over £1 billion in life sciences investments involving companies such as Kindeva and Vertex, supported by nearly £70 million in public funds.
The company, which plans to invest £500 million in the UK over the next decade, revealed its Manchester expansion plans in October 2025. The new facility, expected to open in 2028, will house approximately 300 employees, representing about one-fifth of Convatec's UK workforce. These staff will include transfers from an existing site in Deeside, North Wales, where Convatec will maintain its manufacturing operations.
Convatec had requested up to £40 million in grant assistance through negotiations with the Office for Life Sciences to finance the expansion, which involves adding laboratory space and purchasing new equipment. Jonny Mason, Convatec’s chief executive and an alumnus of the University of Manchester, emphasized the importance of government support, noting that while operational costs in Manchester are higher than in other countries, the region’s skilled talent pool makes the investment attractive. Mason acknowledged the need to evaluate alternative options internationally to protect shareholder interests but praised the role of government backing in advancing the Manchester project.
The company has also collaborated with the office of Andy Burnham, former mayor of Greater Manchester, whose leadership has focused on devolution and local economic development.
Convatec’s recent financial update showed stronger-than-expected performance for the first ten months of 2026. Organic revenue growth reached 6.6 percent, excluding sales of InnovaMatrix, a wound treatment product affected by insurance reimbursement changes in the United States, the company’s largest market. Growth in the continence and infusion care segments contributed to the improved results.
Following this update, Convatec raised its full-year organic revenue growth forecast to between 6.25 percent and 7 percent, an increase from the previous range of 5.5 percent to 6.5 percent. The company also reaffirmed its medium-term ambitions, projecting organic revenue growth of 6 to 8 percent annually and an adjusted operating margin in the mid-20s percentage range starting in 2027.
The positive results drove Convatec’s share price up 9.4 percent to 270 pence on the London Stock Exchange, increasing its market value to £5 billion. The company, founded in 1978, has approximately 10,000 employees worldwide and operates in nearly 90 countries.
Analysts at UBS described the trading update as "very strong," highlighting that the reaffirmation of medium-term guidance addressed key investor concerns. They noted that robust underlying growth enhances Convatec’s ability to absorb inflationary pressures while continuing to invest in product launches. UBS anticipates further positive market reactions as Convatec’s prospects for 2026 improve and risks for 2027 decline, despite the stock currently trading at a discount compared to peers with similar growth profiles.
Mason also indicated that while inflation is expected to rise modestly next year, the company remains on track to meet its financial projections.
